Status:
COMPLETED
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
Lead Sponsor:
Capital Medical University
Conditions:
Malignant Tumor
Eligibility:
All Genders
18-80 years
Brief Summary
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immun...
Detailed Description
1. The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally. 2. Malignant cavity effusion from cancer patients is obtained thr...
Eligibility Criteria
Inclusion
- Histologically confirmed with malignant tumor and malignant cavity effusion.
- An Eastern Cooperative Oncology Group（ECOG）performance status of 0-2.
- Normal cardiac, hepatic, renal and bone marrow functions.
- Life expectancy \>3 months.
- Not receive other anti-tumor treatment.
- Not receive chemotherapy in pleural and abdominal cavity.
Exclusion
- Previous history of other malignancies.
- Serious or uncontrolled concurrent medical illness.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01884168
Start Date
March 1 2013
End Date
May 1 2023
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital Medical University Cancer Center/Beijing Shijitan Hospital
Beijing, Beijing Municipality, China, 100038